摘要
目的:探讨阿立哌唑与氯丙嗪对女性精神分裂症患者的疗效及安全性。方法:对68例女性精神分裂症患者随机分为两组,分别给予阿立哌唑与氯丙嗪治疗,疗程8周。用阳性与阴性症状量表(PANSS)与副反应量表(TESS)评定疗效和不良反应。结果:两组总的疗效差异无显著性(P>0.05),但阿立哌唑起效较快;且在治疗阴性症状方面,以阿立哌唑显著较好(P<0.05)。阿立哌唑组不良反应较氯丙嗪组少,其中震颤、静坐不能、视物模糊、心动过速显著少于氯丙嗪组(P<0.05)。结论:阿立哌唑是一种安全有效的抗精神病药。
Objective:To detect the clinical efficacy and side effects of aripiprazole and chlorpromazine in the treatment of female schizophrenic patients. Methods :68 female schizophrenic patients have been divided into aripiprazole group and chlorpromazine group randomly to treat for 8 weeks . Positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and side effects respectively. Results: There were no significant difference between two groups( P 〉 0.05 ). However, Aripiprazole took effect more quickly. But, Significant difference were found between two groups in the reduction rate of scale about negative symptoms ( P 〈 0.05 ). Patients in aripiprazole group reported much fewer side effects than those in eblorpromazine group, especially in the items of tremor, skathisia, blur sight and tachycardia on TESS( P 〈 0.05 ). Conclusions: Aripiprazole is an effective antipsyshotic drug with fewer side effects.
出处
《中国民康医学》
2006年第17期719-720,共2页
Medical Journal of Chinese People’s Health
关键词
精神分裂症
阿立哌唑
氯丙嗪
Schizophrenia
Aripiprazole
Chlorpromazine